Arterial blood pressure and baroreflex sensitivity 1 - 18 years after completing anthracycline therapy

Neoplasma

Volumn 54, Issue 2, 2007, Pages 162-167

  Novakova Z ^a   Balcarkova P ^b   Honzikova N ^a   Fiser B ^a   Zavodna E ^a   Hrstkova H ^c   Krontoradova K ^c   Stastna J ^c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Anthracyclines; Baroreflex sensitivity; Blood pressure; Cardiotoxicity

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; RAZOXANE; VINCA ALKALOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BREATHING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; DIGITAL ARTERY; FEMALE; GROUPS BY AGE; HEART BEAT; HUMAN; INFANT; INTERMETHOD COMPARISON; MALE; PRESSORECEPTOR REFLEX; SENSITIVITY AND SPECIFICITY; ACUTE LYMPHOCYTIC LEUKEMIA; ARTERY; BLOOD PRESSURE; BODY MASS; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HEART RATE; HODGKIN DISEASE; METABOLISM; MONITOR; NONHODGKIN LYMPHOMA; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTHRACYCLINES; ARTERIES; BAROREFLEX; BLOOD PRESSURE; BLOOD PRESSURE MONITORS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HEART RATE; HODGKIN DISEASE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE;

EID: 34347222218     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. PAI VB, NAHATA MC. Cardiotoxicity of chemotherapeutic agents. Drug Safety 2000; 22: 236-302.
2. MEINARDI MT, VAN DER GRAAF WTA, VAN VELDHUISEN DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treatment Rev 1999; 25: 237-247.
3. SHAN K, LINCOFF AM, YOUNG JB. Anthracycline-induced cardiotoxicity. Annals Internal Med 1996; 125: 47-58.
4. GERŠL V, BAJGAR J, KRS O, et al. Changes in cholinesterase activities after daunorubicin administration to rabbits. Hum Experim Toxicol 1996; 15: 834-838. (Pubitemid 26372031)
5. SAKAI T, INAGKI R, TANIGUCHI T, et al. Persistent release of noradrenaline caused by anticancer drug 4'-epidoxorubicin in rat tail artery in vitro. Eur J Pharmacol 1998; 356: 25-30.
6. JÍRA M, ZÁVODNÁ E, HONZÍKOVÁ N, NOVÁKOVÁ Z, FIŠER B. Baroreflex sensitivity as an individual characteristic feature. Physiol Res 2006; 55: 349-351.
7. GRIBBIN B, PICKERING EG, SLEIGHT P, PETO R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res 1971; 29: 424-431.
8. LA ROVERE MT, BIGGER JT, MARCUS FI et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) investigators. Lancet 1998; 351: 478-484.
9. HONZÍKOVÁ N, FIŠER B, SEMRÁD B, LÁBROVÁ R: Baroreflex sensitivity determined by spectral method and heart rate variability, and two-years mortality in patients after myocardial infarction. Physiol Res 2000; 49: 643-650. (Pubitemid 32066762)
10. HONZÍKOVÁ N, NOVÁKOVÁ Z, ZÁ VODNÁ E, et al. Baroreflex sensitivity in children, adolescents and young adults with essential and white-coat hypertension; Klin Pädiatr 2006; 218: 237-242.
11. RUIZ J, MONBARON D, PARATI G, et al. Diabetic neuropathy is a more important determinant of baroreflex sensitivity than carotid elasticity in type 2 diabetes. Hypertension 2005; 46: 162-167.
12. SMYTH HS, SLEIGHT P, PICKERING GW. Reflex regulation of arterial pressure during sleep in man: A quantitative method of assessing baroreflex sensitivity. Circ Res 1969; 3: 476-485.
13. PIHKALA J, SAARINEN UM, LUNDSTROM U, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996; 32A: 97-103. (Pubitemid 26086331)
14. LIPSHULTZ SE, COLAN SD, GELBERG RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia of childhood. N Eng J Med 1991; 324: 808-815.
15. SILBER JH, JAVKAI RI, LARSEN RL, et al. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Onco 1993; 21: 477-479. (Pubitemid 23246302)
16. SCHWARTZ RG, MC KENZIE WB, ALEXANDER J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven year experience using serial radionuclide angiocardiography. Am J Med 1978; 82: 1109-1118.
17. RADERER M, MACE T, KASTNER J, et al. Tolerance of novel chemosensitizer dexverapamil in combination with anthracycline chemotherapy: A prospective toxicity analysis in advanced gastrointestinal cancer. Onkologie 1995; 18: 462-467.
18. SPATH-SCHWALBE E, LANGE E, GENVRESSE I, et al. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma - a phase II study. Anti Cancer Drugs 2002; 13: 395-403. (Pubitemid 34454725)
19. LANZARINI L, BOSSI G, LAUDISA ML, KLERSY C, ARICO M. Lack of clinically significant dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am Heart J 2000; 140: 315-323.
20. EKHOLM E, RANTANEN V, BERGMAN M, et al: Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients. Anticancer Research 2000; 20: 2045-2048.
21. WEESNER KM, BLEDSOME M, CHAUVENET A, WOFFORD M. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 1991; 68: 435-438.
22. HRSTKOVÁ H, HONZÍKOVÁ N, FIŠER B, ZÁVODNÁ E, NOVOTNÝ J.. Relationship between anamnestically assessed physical activity and baroreflex sensitivity after anthracycline (in Czech). Česko-Slovenská pediatrie 2000; 55: 281-287.
23. HRSTKOVÁ H, HONZÍKOVÁ N, FIŠER B, NOVÁKOVÁ Z. Baroreflex sensitivity, blood pressure and heart rate variability after anthracycline treatment for malignant tumour. Scripta Medica 2001; 74: 187-194. (Pubitemid 34177142)
24. ZÁVODNÁ E, HRSTKOVÁ H, HONZÍKOVÁ N, NOVÁKOVÁ Z. Autonomous regulation of circulation in children after anthracycline therapy. Scripta Medica 2002; 75: 195-202.
25. ZÁVODNÁ E, HRSTKOVÁ H, BALCÁRKOVÁ P, NOVÁKOVÁ Z, HONZÍKOVÁ N, FIŠER B. Blood pressure and baroreflex sensitivity after anthracycline therapy in childhood with respect to fatty acid metabolism. Scripta Medica 2005; 78: 257-264.
26. HRSTKOVÁ H, HONZÍKOVÁ N, FIŠER B, NOVÁKOVÁ Z. Age and circulatory variables after anthracycline treatment. In: XXII International Congress of Pediatrics. Book of abstracts. Amsterdam 1998; 383P.
27. ZÁVODNÁ E, HRSTKOVÁ H, HONZÍKOVÁ N, FIŠER B. Relationship between anamnestic determined physical activ ity and baroreflex sensitivity after anthracycline treatment. Physiol Res 2000; 49: 18P.
28. ZÁVODNÁ E, HRSTKOVÁ H, NOVÁKOVÁ Z, HONZÍKOVÁ N. Long-term changes in cardiovascular regulation in paediatric oncology patients. Slovenska Pediatria 2004; 11: 35.
29. NOVÁKOVÁ Z, ZÁVODNÁ E, HONZÍ KOVÁ N, HRSTKOVÁ H. Baroreflex sensitivity in children and adolescents after antitumour therapy with respect to fatty acid metabolism. Physiol Res 2004; 53: 27P.
30. ELBL L, HRSTKOVA H, TOMASKOVA I, MICHALEK J. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF) in pediatric patients: echocardiographic follow up. Support Care Cancer 2006; 14: 128-136.
31. HRSTKOVÁ H, ELBL L, NOVÁKOVÁ Z, et al. Cardiotoxicity and baroreflex sensitivity in children treated with anthracycline for leukaemia. Physiol Res 2004; 53: 51P.
32. CONSTANT I, LAUDE D, ELGHOZI JL, MURAT I. Assessment of short-term blood pressure variability in anesthetized children: A comparative study between intraarterial and finger blood pressure. J Clin Monit Comput 1999; 15: 205-214.
33. TANAKA H, THULESIUS O, YAMAGUCHI H, MINO M, KONISHI K. Continuous non-invasive finger blood pressure monitoring in children. Acta Paediatr 1994; 83: 646-652. (Pubitemid 24197623)
34. ZÁVODNÁ E, HRSTKOVÁ H, HONZÍKOVÁ N, NOVÁKOVÁ Z, FIŠER B. Physiological values of finger arterial pressure and baroreflex sensitivity for the age between 11-21 years. Physiol Res 2005; 54: 48P.